Studies such as those discussed in this section highlight the importance of mesothelin as a potential target antigen in ovarian cancer CAR-T therapy, and the fact that researchers have put a tremendous deal of effort into assessing CAR-T therapy in the treatment of mesothelin-positive ovarian cancer; however, the findings of future clinical trials with larger patient populations could shed more light on the downsides and upsides of ovarian cancer CAR-T therapy, and propose applicable strategies for overcoming the limitations. Here, MSLN is linked to ovarian carcinoma.